

DAFTAR PUSTAKA

- Anolik, J.H. B Cell Biology And Dysfunction In SLE. Bulletin of the NYU Hospital for Joint Diseases, 2007, 65(3): 182-186
- Aoki S, 2005. Histological Features of Rheumatoid Arthritis Patients Having Antibodies to Enterobacterial Common Antigens: Correlation of Antibody Levels with Semiquantitative Histologic Scores and Laboratory Markers. Clinical and Experimental Rheumatology. 23:13-18
- Bas DB, Sue J, Sandor K, Agalave NM, Lundberg J, Codeluppi S, *et al.* 2012. Collagen Antibody-Induced Arthritis Evokes Persistent Pain With Spinal Glial Involvement and Transient Prostaglandin Dependency. American College of Rheumatology, vol. 64 No. 12 Desember 2012, pp 3886-3896
- Bartels CM., 2011. Systemic Lupus Erythematosus (LES), (*Online*), (<http://emedicine.medscape.com/article/332244-overview>, diakses 10 Februari 2016)
- Bertisias G, Cervera R, Boumpas DT. 2012. Systemic Lupus Erythematosus : Pathogenesis and Clinical Features 20:477-478.
- Bertisias GK, Ioannidis JP, Aringer M, *et al.* EULAR Recommendations For The Management Of Systemic Lupus Erythematosus With Neuropsychiatric Manifestations: Report Of A Task Force Of The EULAR Standing Committee For Clinical Affairs. *Ann Rheum Dis.* Dec 2010 ;69(12):2074-82.
- Calvani N¹, Caricchio R, Tucci M, Sobel ES, Silvestris F, Tartaglia P, Richards HB. 2005, Induction Of Apoptosis By The Hydrocarbon Oil Pristane: Implications For Pristane-Induced Lupus. *J Immunol.* 2005 Oct 1;175(7):4777-82.
- Chowdhary, V.R., Grande, J.P., Luthra, H.S., David, C.S. 2007. *Characterization of haemorrhagic pulmonary capillaritis: another manifestation of Pristane induced lupus.* *Rheumatology*, 46(9): 1405-1410
- Cui, G.M., Liu, G., Liu, W., Kan, B., Mao, Y.Q., Wei, Y.Q. Experimental Study Of Pristane-Induced Murine Lupus Model. *Sichuan Da XueXueBao Yi Xue Ban*, 2006,37(2): 309-312
- Edworthy SM. Clinical Manifestations of Systemic Lupus Erythematosus. In: Harris ED, *et al*, eds. *Kelley's Textbook of Rheumatology*. 7th ed. Philadelphia, Pa: WB Saunders; 2005:1201-24.
- Firestein GS, Budd RC, Harris ED Jr, *et al*, eds., 2008. *Kelley's Textbook of Rheumatology*. 8th ed. Philadelphia, Pa: Saunders Elsevier: 656-65.

Gladman DD, Urowitz MB, Chaudhry-Ahluwalia V, Hallet DC, Cook RJ. Predictive Factors For Symptomatic Osteonecrosis In Patients With Systemic Lupus Erythematosus. *J Rheumatol*. Apr 2001;28(4):761-5.

Hau, J. dan Hoosier, G.I. 2003. *Handbook of Laboratory Animal Science Second Edition*. Boca Raton: CRC Press. p.539-542

Hayashi, T., Hasegawa, K., Adachi, C. 2005. Elimination of CD4(+)CD25(+) T cell accelerates the development of glomerulonephritis during the preactive phase in autoimmune-prone female NZB x NZW F mice. *International Journal of Experimental Pathology*, 86:289-296

Hazani R, Engineer N. 2008. "Surreptitious injection of mineral oil: a case report of sclerosing lipogranulomatosis". *Ann Plast Surg* 61 (5): 555–8. doi:10.1097/SAP.0b013e31816d8316. PMID 18948786.

Hunt, J. 2002. "Early developments in petroleum geochemistry". *Organic Geochemistry* 33: 1025–1052. doi:10.1016/S0146-6380(02)00056-6.

Jaekel HP, Klopsch T, Benkenstein B, et al: Reactivities to the Sm autoantigenic complex and the synthetic SmD1-aa83-119 peptide in systemic lupus erythematosus and other autoimmune diseases. *J Autoimmun*. 2001 17:347–354.

Jennekens FG, Kater L. The Central Nervous System In Systemic Lupus Erythematosus. Part 1. Clinical syndromes: a literature investigation. *Rheumatology (Oxford)*. Jun 2002;41(6):605-18.

Jennekens FG, Kater L. The Central Nervous System In Systemic Lupus Erythematosus. Part 2. Pathogenetic Mechanisms Of Clinical Syndromes: A Literature Investigation. *Rheumatology (Oxford)*. Jun 2002;41(6):619-30

Kalim, H. 2000. Gambaran Klinik dan Harapan Hidup Penderita Lupus Eritematosus Sistemik (SLE). *Majalah Kedokteran Indonesia*, 46: 383-384.

Lahita RG. The clinical presentation of systemic lupus erythematosus. In: Lahita RG, Tsakos G, Buyon, J, Koike T. Editors. *Systemic Lupus Erythematosus*, 5 th ed. San Diego. Elsevier; 2011: 525-540

Leiss H¹, Niederreiter B, Bandur T, Schwarzecker B, Blüml S, Steiner G, Ulrich W, Smolen JS, Stummvoll GH. Pristane-Induced Lupus As A Model Of Human Lupus Arthritis: Evolvement Of Autoantibodies, Internal Organ And Joint Inflammation. *NCBI, Lupus*. 2013 Jul;22(8):778-92. doi: 10.1177/0961203313492869.

Livingston B, Bonner A, Pope J. Differences In Clinical Manifestations Between Childhood-Onset Lupus And Adult-Onset Lupus: A Meta-Analysis. *Lupus*. Nov 2011;20(13):1345- 55.

- Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Induction And Maintenance Therapy For Lupus Nephritis: A Systematic Review And Meta-Analysis. *Lupus*. 2010;19:703–710
- Manson JJ, Ma A, Rogers P, et al: Relationship Between Anti-Dsdna, Anti-Nucleosome And Anti-Alpha-Actinin Antibodies And Markers Of Renal Disease In Patients With Lupus Nephritis: A Prospective Longitudinal Study. *Arthritis Res Ther* 11:R154, 2009.
- Minhas, U; P Das dan A Bhatnagar. 2011. Role of reactive intermediates in the immunopathogenesis of the pristane-induced Balb/c model of lupus 20, 1421–1425.
- Mizutani, A., Shaheen, V.M., Yoshida, H., et al. 2005. *Pristane-induced autoimmunity in germ-free mice*. *Clinical Immunology*, 114(2): 110-118
- Mok, C.C., Lau, C.S, 2003. *Pathogenesis of systemic lupus erythematosus*. *J ClinPathol*, 56:481-490
- Oinuma K, Harada Y, Nawata Y, Takabayashi K, Abe I, Kamikawa K, et al. Osteonecrosis In Patients With Systemic Lupus Erythematosus Develops Very Early After Starting High Dose Corticosteroid Treatment. *Ann Rheum Dis*. Dec 2001;60(12):1145-8
- Perry, D., Sang, A., Vin, Y., Zheng, Y., dan Morel, L. 2011. Murine Models Of Systemic Lupus Erythematosus. *Journal Of Biomedicine And Biotechnology*, ID 271694: 1-9
- Reeves, W.H. Lee, P.Y., Weinstein, J.S., Satoh, M., Lu, L. 2009. Induction Of Autoimmunity By Pristane And Other Naturally Occurring Hydrocarbons. *Trends in Immunology*, 30(9): 455-464
- Reeves, W.H. Lee, P.Y., Weinstein, J.S., Satoh, M., Lu, L. 2009. Induction Of Autoimmunity By Pristane And Other Naturally Occurring Hydrocarbons. *Trends in Immunology*, 30(9): 455-464
- Rottman, J.B. Willis, C.R. 2010. *Mouse models of systemic lupus erythematosus reveal a complex pathogenesis*. *Veterinary Pathology*, 47(4): 4664-4676
- Rus, V., Maury, E.E., Hochberg, M.C. 2007. *The Epidemiology of Systemic Lupus Erythematosus*. In: Wallace, Daniel J, Hahn, BevrHannahs. *Dubois' Lupus Erythematosus 7th ed*. California: Lippincott Williams &Walkins
- Satoh, M., Hamilton, K.J., Aimani, A.K., Dong, X., Wang, J., Kanwar, Y.S., Reeves, W.H. 1996. *Autoantibodies to ribosomal P antigens with immune complex glomerulonephritis in SJL mice treated with pristane*. *J immunol*, 157(7): 3200-3206

- Satoh, M., Kumar, A., Kanwar, Y.S., Reeves, W.H. 1995/ *Anti-nuclear antibody production and immune-complex glomerulonephritis in Balb/c mice treated with pristane*. ProcNatSci USA, 92(24): 10934-10938
- Satoh, M., Richards, H.B., Shaheen, V.M., Yoshida, H., Shaw, M., Naim, J.Q., Wooley, P.H., Reeves, W.H. 2000. *Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane*. ClinExpImmunol, 121(2): 399-405
- Satoh, M., Treadwell, E.L., Reeves, W.H. 1995. *Pristane induces high titers of anti-Su and anti-nRNP/Sm autoantibodies in Balb/c mice. Quantitation by antigen captor ELISAs based on monospecific human autoimmune sera*. J Immunol Methods, 182(1): 51-62
- Shakra, M.A. 2008. Do improved survival rates of patients with systemic lupus erythematosus reflect a global trend?. *The Journal of Rheumatology*. 35: 1906-1908
- Shmerling RH. Autoantibodies In Systemic Lupus Erythematosus – There Before You Know It. New Eng J Med 2003;349:16.
- Timothy B. Niewold,¹ Daniel N. Clark,² Rafah Salloum,¹ and Brian D. Poole². 2010, Interferon Alpha in Systemic Lupus Erythematosus. *Journal of Biomedicine and Biotechnology*, ID 948364: 8 pages.
- Timothy B. Niewold. 2011, Interferon Alpha as a Primary Pathogenic Factor in Human Lupus. *J Interferon Cytokine Res*. Dec 2011; 31(12): 887–892.
- Wallace J. and Hannah Bevr., 2013. *Dubois' Lupus Erythematosus And Related Syndromes*, Volume 8, Elsevier Saunders, Philadelphia, p.191.
- Wallace J. and Hannah Bevr., 2013. *Dubois' Lupus Erythematosus And Related Syndromes*, Volume 8, Elsevier Saunders, Philadelphia, p.281.
- Wallace, Daniel J. 2006. The Clinical Presentation of Systemic Lupus Erythematosus; Differential Diagnosis and Disease Association. In: Wallace, Daniel J, Hahn, Bevr Hannahs. *Dubois' Lupus Erythematosus 7th ed*. California: Lippincott Williams & WalkinsYang et al., 2011
- Westley H., Pui Y., dan Wes Y. Monocyte and Macrophage Abnormalities in Systemic Lupus Erythematosus. *Arch Immunol Ther Exp (Warsz)*. 2010 October ; 58(5): 355–364.
- Yuriawantini, Suryana. Aspek Immunologi LES. *J Peny Dalam Vol 8*, 2007; 234-235
- Zhou, H., Beevers, C.S., Huang, S. 2011. Targets Of Curcumin. *Curr Drug Targets*, 12(3): 332-47